Literature DB >> 22453181

PRND 3'UTR polymorphism may be associated with behavioral disturbances in Alzheimer disease.

Marcin Flirski1, Monika Sieruta, Ewa Golańska, Iwona Kłoszewska, Paweł P Liberski, Tomasz Sobów.   

Abstract

The etiology of behavioral and psychological symptoms of dementia (BPSD) is complex, including putative biological, psychological, social and environmental factors. Recent years have witnessed accumulation of data on the association between genetic factors and behavioral abnormalities in Alzheimer disease (AD). In this research paper, our aim is to evaluate the association between the APOE, CYP46, PRNP and PRND genes and the profile of neuropsychiatric symptoms in Polish subjects with AD and mild cognitive impairment (MCI). We studied 99 patients with AD and 48 subjects with MCI. The presence and profile of BPSD were evaluated at baseline and prospectively with the Neuropsychiatric Inventory (NPI). Patients were dichotomized into those having ever experienced a particular symptom and those who did not over the whole disease period. Genotyping was performed using previously described standard protocols. The prevalence of comorbid behavioral symptoms and the overall level of behavioral burden were significantly greater in AD compared with the MCI group. In AD patients, carrier status of the T allele of the 3'UTR (untranslated region) PRND polymorphism was associated with an increased cumulative behavioral load and an elevated risk for delusions, anxiety, agitation/aggression, apathy and irritability/emotional ability. Among MCI subjects, APOE ε4 carriers demonstrated a reduced risk for nighttime behavior change. No other statistically significant genotype-phenotype correlations were observed, including the APOE, CYP46 and PRNP genes. A precise estimation of the exact significance of particular polymorphisms in BPSD etiology requires future studies on large populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22453181      PMCID: PMC3338968          DOI: 10.4161/pri.6.1.18428

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  36 in total

1.  24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.

Authors:  A Papassotiropoulos; D Lütjohann; M Bagli; S Locatelli; F Jessen; R Buschfort; U Ptok; I Björkhem; K von Bergmann; R Heun
Journal:  J Psychiatr Res       Date:  2002 Jan-Feb       Impact factor: 4.791

2.  First report of polymorphisms in the prion-like protein gene (PRND): implications for human prion diseases.

Authors:  K Peoc'h; C Guérin; J P Brandel; J M Launay; J L Laplanche
Journal:  Neurosci Lett       Date:  2000-06-02       Impact factor: 3.046

3.  A simple and efficient method for apolipoprotein E genotype determination.

Authors:  J Chapman; J Estupiñan; A Asherov; L G Goldfarb
Journal:  Neurology       Date:  1996-05       Impact factor: 9.910

4.  Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease.

Authors:  M S Palmer; A J Dryden; J T Hughes; J Collinge
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

5.  The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease.

Authors:  A L Pritchard; J Harris; C W Pritchard; J Coates; S Haque; R Holder; P Bentham; C L Lendon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-15       Impact factor: 10.154

Review 6.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

7.  The prion gene is associated with human long-term memory.

Authors:  Andreas Papassotiropoulos; M Axel Wollmer; Adriano Aguzzi; Christoph Hock; Roger M Nitsch; Dominique J-F de Quervain
Journal:  Hum Mol Genet       Date:  2005-06-29       Impact factor: 6.150

Review 8.  Cyp46 polymorphisms in Alzheimer's disease: a review.

Authors:  Anália Nusya Medeiros Garcia; Maria Tereza Cartaxo Muniz; Hugo Rafael Souza e Silva; Helker Albuquerque da Silva; Luiz Athayde-Junior
Journal:  J Mol Neurosci       Date:  2009-08-25       Impact factor: 3.444

9.  Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD.

Authors:  E Golanska; K Hulas-Bigoszewska; E Rutkiewicz; M Styczynska; B Peplonska; M Barcikowska; J Bratosiewicz-Wasik; P P Liberski
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

10.  Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease.

Authors:  Kristina F Zdanys; Timothy G Kleiman; Martha G MacAvoy; Benjamin T Black; Tracy E Rightmer; Monique Grey; Katherine S Garman; Rajesh R Tampi; Joel Gelernter; Christopher H van Dyck
Journal:  Neuropsychopharmacology       Date:  2006-07-12       Impact factor: 7.853

View more
  3 in total

1.  Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients.

Authors:  Supharat Suvichapanich; Sukanya Wattanapokayakit; Taisei Mushiroda; Hideki Yanai; Charoen Chuchottawon; Tassawan Kantima; Supalert Nedsuwan; Wimon Suwankesawong; Cholticha Sonsupap; Roongkarn Pannarunothai; Sukanya Tumpattanakul; Warawut Bamrungram; Achara Chaiwong; Surakameth Mahasirimongkol; Sasithorn Mameechai; Weerapat Panthong; Nantawan Klungtes; Amara Munsoo; Udomrat Chauychana; Molrudee Maneerat; Koya Fukunaga; Yosuke Omae; Katsushi Tokunaga
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Behavioral and psychological symptoms in Alzheimer's disease.

Authors:  Xiao-Ling Li; Nan Hu; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Biomed Res Int       Date:  2014-07-15       Impact factor: 3.411

3.  Gene expression and functional annotation of human choroid plexus epithelium failure in Alzheimer's disease.

Authors:  Arthur A Bergen; Sovann Kaing; Jacoline B ten Brink; Theo G Gorgels; Sarah F Janssen
Journal:  BMC Genomics       Date:  2015-11-16       Impact factor: 3.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.